Thyrogen® (thyrotropin alfa for injection) is a highly purified recombinant source of human thyroid stimulating hormone (rhTSH) developed for use in well-differentiated thyroid cancer patients who have had near-total or total thyroidectomy, and who must therefore take thyroid hormones and undergo periodic testing for recurrent or persistent cancer. Thyrogen raises serum TSH levels exogenously, stimulating I-131 uptake and thyroglobulin (Tg) production and release by cells of thyroid origin.
Thyrogen is indicated for use as an adjunctive diagnostic tool for serum Tg testing with or without radioiodine whole body scans (WBS) in the follow-up of patients with well-differentiated thyroid cancer.
Thyrogen is also indicated for use as an adjunctive treatment for radioiodine ablation of the thyroid tissue remnant in patients who have undergone a near total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic disease.
Potential clinical uses include:
For more information, please see the full prescribing information .
Genzyme and Thyrogen
Genzyme has been committed to helping patients with well-differentiated thyroid cancer since the 1980s, when they were among the first to research rhTSH. Further important milestones in Thyrogen's development include:
To date, an estimated 350,000 patients worldwide have received Thyrogen, in 55 countries and Genzyme continues its commitment to thyroid cancer and other endocrine research.
The pharmacokinetics of Thyrogen were studied in 16 patients with well-differentiated thyroid cancer given a single 0.9 mg IM dose. Mean peak concentrations of 116 ± 38 mU/L were reached between 3 and 24 hours after injection (median of 10 hours). The mean apparent elimination half-life was 25 ± 10 hours.
Download these resources about thyroid cancer and Thyrogen for your patients.